SABCS 2022 | SOLTI-1503 PROMETEO: T-VEC + atezolizumab in patients with residual BC after neoadjuvant chemo

Chemo-resistant residual disease remains a major unmet clinical need for patients with HER2-negative breast cancer following neoadjuvant chemotherapy. Tomás Pascual, MD, Hospital Clinic Barcelona, Barcelona, Spain, provides an overview of the Phase II PROMETEO (NCT03802604) trial exploring the oncolytic virus, T-VEC, with atezolizumab in patients with HER2-negative breast cancer and residual disease following standard neoadjuvant chemotherapy and prior to surgery. The primary objective was to evaluate the efficacy of the combination, measured by the rate of residual cancer burden class 0/1 at surgery. Radiological response by MRI was achieved by 3 of 28 pts (10.7%). Notably, none of the 7 patients with a pathologic complete response (pCR) had radiological response. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.